CL2012000533A1 - Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros. - Google Patents
Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros.Info
- Publication number
- CL2012000533A1 CL2012000533A1 CL2012000533A CL2012000533A CL2012000533A1 CL 2012000533 A1 CL2012000533 A1 CL 2012000533A1 CL 2012000533 A CL2012000533 A CL 2012000533A CL 2012000533 A CL2012000533 A CL 2012000533A CL 2012000533 A1 CL2012000533 A1 CL 2012000533A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- phobia
- agoraphobia
- thiazole
- prophylaxis
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 3
- 208000008811 Agoraphobia Diseases 0.000 title abstract 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 title abstract 2
- 206010034912 Phobia Diseases 0.000 title abstract 2
- 206010041250 Social phobia Diseases 0.000 title abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000019906 panic disease Diseases 0.000 title abstract 2
- 208000019899 phobic disease Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000028173 post-traumatic stress disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un agente para el trastorno y/o profilaxis de un tratamiento de ansiedad que comprende un compuesto derivado de tiazol o una de sus sales, en donde el trastorno de ansiedad es un trastorno de pánico, agorafobia, trastorno obsesivo-compulsivo, fobia social, trastorno de estrés post-traumático, fobia particular, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009202894 | 2009-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000533A1 true CL2012000533A1 (es) | 2012-09-14 |
Family
ID=43649340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000533A CL2012000533A1 (es) | 2009-09-02 | 2012-02-29 | Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20120172362A1 (es) |
| EP (1) | EP2474544B1 (es) |
| JP (1) | JP5663485B2 (es) |
| KR (2) | KR20120047311A (es) |
| CN (1) | CN102482271A (es) |
| AU (1) | AU2010290424C1 (es) |
| BR (1) | BR112012004850A2 (es) |
| CA (1) | CA2772922C (es) |
| CL (1) | CL2012000533A1 (es) |
| CY (1) | CY1119483T1 (es) |
| DK (1) | DK2474544T3 (es) |
| DO (1) | DOP2012000056A (es) |
| EA (1) | EA023728B1 (es) |
| ES (1) | ES2643840T3 (es) |
| GE (1) | GEP20156225B (es) |
| HR (1) | HRP20171418T1 (es) |
| HU (1) | HUE036543T2 (es) |
| IL (1) | IL218320A (es) |
| LT (1) | LT2474544T (es) |
| MA (1) | MA33619B1 (es) |
| ME (1) | ME02877B (es) |
| MX (1) | MX2012002529A (es) |
| NZ (1) | NZ598754A (es) |
| PL (1) | PL2474544T3 (es) |
| PT (1) | PT2474544T (es) |
| RS (1) | RS56401B1 (es) |
| SI (1) | SI2474544T1 (es) |
| SM (1) | SMT201700465T1 (es) |
| TN (1) | TN2012000093A1 (es) |
| UA (1) | UA113383C2 (es) |
| WO (1) | WO2011027806A1 (es) |
| ZA (1) | ZA201202347B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4638355B2 (ja) * | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| MA41090A (fr) * | 2014-12-03 | 2017-10-10 | H Lundbeck As | Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson |
| JO3546B1 (ar) | 2015-01-09 | 2020-07-05 | Kyowa Kirin Co Ltd | طريقة لإنتاج مشتق ثيازول |
| JO3544B1 (ar) * | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
| JP7235859B2 (ja) | 2018-09-17 | 2023-03-08 | ユンジン ファーム．カンパニー、リミテッド | 新規なチアゾール誘導体及びその薬学的に許容される塩 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2176204T3 (es) | 1992-07-08 | 2002-12-01 | Kyowa Hakko Kogyo Kk | Antidepresivos que contienen un derivado de xantina. |
| DE69834500T2 (de) | 1997-09-05 | 2007-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivative zur behandlung von hirnischämie |
| AU4431000A (en) * | 1999-05-12 | 2000-12-05 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| US20040152659A1 (en) * | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
| CA2459304A1 (en) | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| KR20060037252A (ko) * | 2003-06-10 | 2006-05-03 | 교와 핫꼬 고교 가부시끼가이샤 | 불안 장애의 치료 방법 |
| JP4638355B2 (ja) * | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| EP1894930A4 (en) * | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
| US7928098B2 (en) * | 2005-08-02 | 2011-04-19 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic and/or preventive agents for a sleep disorder |
| UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою |
-
2010
- 2010-02-09 UA UAA201203922A patent/UA113383C2/uk unknown
- 2010-09-02 JP JP2011529927A patent/JP5663485B2/ja not_active Expired - Fee Related
- 2010-09-02 RS RS20170966A patent/RS56401B1/sr unknown
- 2010-09-02 CN CN2010800392099A patent/CN102482271A/zh active Pending
- 2010-09-02 SM SM20170465T patent/SMT201700465T1/it unknown
- 2010-09-02 ME MEP-2017-233A patent/ME02877B/me unknown
- 2010-09-02 EA EA201270360A patent/EA023728B1/ru not_active IP Right Cessation
- 2010-09-02 LT LTEP10813754.8T patent/LT2474544T/lt unknown
- 2010-09-02 KR KR1020127008310A patent/KR20120047311A/ko not_active Ceased
- 2010-09-02 PT PT108137548T patent/PT2474544T/pt unknown
- 2010-09-02 WO PCT/JP2010/064989 patent/WO2011027806A1/ja not_active Ceased
- 2010-09-02 GE GEAP201012648A patent/GEP20156225B/en unknown
- 2010-09-02 CA CA2772922A patent/CA2772922C/en not_active Expired - Fee Related
- 2010-09-02 MX MX2012002529A patent/MX2012002529A/es active IP Right Grant
- 2010-09-02 ES ES10813754.8T patent/ES2643840T3/es active Active
- 2010-09-02 US US13/393,068 patent/US20120172362A1/en not_active Abandoned
- 2010-09-02 HR HRP20171418TT patent/HRP20171418T1/hr unknown
- 2010-09-02 AU AU2010290424A patent/AU2010290424C1/en not_active Ceased
- 2010-09-02 PL PL10813754T patent/PL2474544T3/pl unknown
- 2010-09-02 DK DK10813754.8T patent/DK2474544T3/en active
- 2010-09-02 NZ NZ598754A patent/NZ598754A/en not_active IP Right Cessation
- 2010-09-02 EP EP10813754.8A patent/EP2474544B1/en active Active
- 2010-09-02 SI SI201031544T patent/SI2474544T1/sl unknown
- 2010-09-02 KR KR1020177010507A patent/KR20170044768A/ko not_active Ceased
- 2010-09-02 BR BR112012004850-3A patent/BR112012004850A2/pt not_active Application Discontinuation
- 2010-09-02 HU HUE10813754A patent/HUE036543T2/hu unknown
-
2012
- 2012-02-26 IL IL218320A patent/IL218320A/en active IP Right Grant
- 2012-02-27 TN TNP2012000093A patent/TN2012000093A1/en unknown
- 2012-02-29 CL CL2012000533A patent/CL2012000533A1/es unknown
- 2012-03-01 DO DO2012000056A patent/DOP2012000056A/es unknown
- 2012-03-30 MA MA34734A patent/MA33619B1/fr unknown
- 2012-03-30 ZA ZA2012/02347A patent/ZA201202347B/en unknown
-
2017
- 2017-10-04 CY CY20171101029T patent/CY1119483T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6751239A2 (es) | Compuesto bicíclico | |
| CR11688A (es) | Compuesto heterociclico | |
| CO7200281A2 (es) | Composicion para control de enfermedades de plantas y aplicacion para la misma | |
| CO6640320A2 (es) | Composición de control de fitoenfermedades y metodo de control de fitoenfermedades | |
| ECSP14013329A (es) | Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas | |
| MX391815B (es) | AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR). | |
| MX2021008281A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| MX2015014385A (es) | Metodo para tratar trastorno de estres post-traumatico. | |
| BRPI1015966A2 (pt) | "método para tratar uma formação subterrânea, e, meio de armazenamento legível por computador." | |
| UY35821A (es) | Compuesto heterocíclico | |
| BRPI0911612A2 (pt) | composições e métodos para o tratamento da esclerose múltipla. | |
| UY34326A (es) | ?Composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan acetolactato sintasa? | |
| IL252981A0 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| CL2012000533A1 (es) | Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros. | |
| ES2421442T3 (es) | Métodos para repeler artrópodos utilizando isolongifolenona | |
| NO20110590A1 (no) | Tid-temperatur indikatorsystem, fremgangsmåte for dets fremstilling samt kombinasjon som omfatter nevnte tid-temperatur indikatorsystem. | |
| MX2016001446A (es) | Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos. | |
| CL2014001157A1 (es) | Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato. | |
| AR100407A1 (es) | Aplicaciones volátiles contra patógenos | |
| UY37502A (es) | Dinucleótido cíclico | |
| BR112014015549A8 (pt) | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção | |
| AR084948A1 (es) | Agente antifungico topico | |
| MX374220B (es) | Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados. | |
| CL2014001127A1 (es) | Metodos y composicion de fumigante que comprende hexafluoropropeno, 1,1,3,3,3-pentafluoropropeno o combinacion de los mismos. | |
| CR11368A (es) | Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida |